Join Biocytogen at 2024 SAPA Annual Conference

We’re excited to announce that Biocytogen will be attending the 2024 SAPA Annual Conference in New Brunswick on September 27 and 28! As leaders in antibody discovery and gene-editing technologies, we look forward to engaging with scientists, industry professionals, and innovators at this renowned event. Join us to discuss cutting-edge research and explore collaborative opportunities!

What is the SAPA?

The Sino-American Pharmaceutical Professionals Association (SAPA), founded in 1993 and headquartered in New Jersey, is one of the most active Chinese professional associations in the U.S. With over 6,000 members from large and mid-sized pharmaceutical and biotech companies, SAPA’s expertise spans across pharmaceutical R&D and production. The organization plays a key role in knowledge exchange within the pharmaceutical, biotechnology, and generic drug industries. Supported by multinational companies, SAPA continues to provide a platform for scientific discussions, talent exchange, and industry training between the U.S. and China.

Event Overview 

​Time: September 27- 28, 2024

Location: Hyatt Regency New Brunswick, 2 Albany St., New Brunswick, NJ 08901

Event Schedule

The Sino-American Pharmaceutical Professionals Association (SAPA) will host its 2024 Annual Conference on September 27 and 28. This year’s event, themed “Redefining Medicine: Navigating Resilience, Transforming Lives,” will feature two plenary sessions and six parallel sessions covering a range of topics, including:

• • Executive & Legal Summit
  • CMC & Outsourcing
  • Career Development
  • Investment & Business Development
  • Drug Discovery
  • Clinical Development & Regulatory Forums

Attendees will have ample opportunities for networking and engagement throughout the conference. The event will culminate in an Annual GALA, offering a delightful dinner, engaging entertainment, and further chances to connect with industry peers and leaders.

About BIOCYTOGEN

Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg). 

We look forward to seeing you at 2024 SAPA Annual Conference in New Brunswick, NJ